Enfortumab vedotin, an antibody–drug conjugate directed against nectin-4, and pembrolizumab, a programmed death 1 (PD-1) inhibitor, have individually been associated with a survival benefit in ...

Results showed that treatment with pembrolizumab plus enfortumab vedotin reduced the risk of disease progression or death by 55% vs chemotherapy (hazard ratio [HR], 0.45 [95% CI, 0.38-0.54]; P ...

References: Yajima S, Hirose K, Masuda H. Enfortumab vedotin with or without pembrolizumab in metastatic urothelial carcinoma: A systematic review and meta-analysis. JAMA Netw Open.Published ...

Enfortumab vedotin plus pembrolizumab also reduced the risk of disease progression or death by 52% versus chemotherapy (HR = 0.48, 95% CI, 0.41-0.57).

Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial cancer, said Evangelia Vlachou, MD, of Johns Hopkins Medicine.

Enfortumab vedotin plus pembrolizumab in advanced bladder cancer: hint of major added benefit. Patients for whom cisplatin-based therapy is unsuitable live significantly longer with the new drug ...

Since September 2024, enfortumab vedotin in combination with pembrolizumab has also been approved for the first-line treatment of unresectable or metastatic urothelial carcinoma.

The positive CHMP opinion is based on data from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) which showed enfortumab vedotin in combination with pembrolizumab significantly ...

- First regimen approved in advanced urothelial cancer to demonstrate superiority to platinum-containing chemotherapy, the standard of care for nearly 40 years1 - European Marketing Authorization ...

Since September 2024, enfortumab vedotin in combination with pembrolizumab has also been approved for the first-line treatment of unresectable or metastatic urothelial carcinoma.

- If approved, enfortumab vedotin in combination with pembrolizumab will be the first and only treatment to offer an alternative to platinum-containing chemotherapy, the current standard of care ...